Pramlintide, an amylin mimetic, is an approved drug for the treatment of insulin-requiring diabetes and has also been studied as a potential treatment for obesity in clinical trials [79]. The gene discussed is IAPP; the disease is obesity due to melanocortin 4 receptor deficiency.